Windlas Biotech Share Price Target 2025, 2026, 2028, 2030, 2040 and 2050

In this article, we will discuss Windlas Biotech Share Price Target 2025, 2026, 2028, 2030, 2040 and 2050 on the basis of growth pattern, technical indicators, market sentiment of last several years. Fundamental and technical analysis will also be analyzed for better understanding of the price prediction of the company. It is very important for a long term investor to have knowledge of all these parameters so that they can set their targets in the future and earn good profits.

What is Windlas Biotech

Windlas Biotech, a company in the Pharmaceuticlas sector, is a famous pharmaceutical company in India, it is known for manufacturing both solid and liquid medicines. The Chairman and Industrial Director of the company is Vivek Dhariwal, it was established on 19 February 2001.

Windlas Biotech discovers and develops new medicines and also produces complex generic products. It serves the semi-urban and rural communities of India with the medicines and Ayurvedic products manufactured by it. Its expansion is spread in more than 14 states of India. Windlas Biotech’s major therapeutic segments are cardiovascular, anti-diabetic, neurological, psychiatric, and respiratory.

Windlas Biotech Fundamental

Windlas Biotech, valued at ₹1,490Cr, has a strong hold in the Indian market, due to which its popularity is increasing among investors. In this financial year, it has given a very good return of 12.91% on the investment of its shareholders and the ROCE of the company is also 17.17%, which shows that the company is using its capital quite efficiently.

Windlas Biotech’s P/E Ratio (TTM) is 25.63 and P/B Ratio is 3.31. Investors are able to earn money but the return percentage is low. The EPS and Book Value Per Share of the company are ₹27.96 and ₹216.51 respectively, which indicates its strong position.

Compared to the financial year 2023, the company has generated 22.80% and 38.09% more sales and profit this year. Its continuously increasing sales and profits for the last 5 years reflect its strong position.

Company Name	Windlas Biotech Ltd.
Sector	Biotechnology & Medical Research
Established	19 February 2001
Website	windlas.com
Listing At	NSE, BSE
Mkt Cap	₹1,490Cr.
ROE	12.91%
ROCE	17.17%
52 Week High	₹794.50
52 Week Low	₹292.05
P/E Ratio (TTM)	25.63
P/B Ratio	3.31
Face Value	5
Book Value Per Share	₹216.51
EPS (TTM)	₹27.96
Dividend Yield	0.77
Net Sales	₹630Cr.
Sales Growth	22.80%
Net Profit (Anual)	₹58Cr.
Profit Growth	38.09%

Windlas Biotech Listing date

Windlas Biotech is listed on both NSE and BSE. It was listed on the stock exchange on August 2, 2021 at Rs 435.

Windlas Biotech Share Price History

When Windlas Biotech company was listed in the stock market, the share price of the company was Rs 435 and today on 19 July 2024, the share price of the company has increased to Rs 694. The company’s shares have increased by 110.40% in the last one year. The current market capital of the company is ₹1,490Cr, which comes under small cap.

The company has given a profit of 31.14% in the last 3 months. Its shares have seen a negative growth of 2.99% and 1.97% in the last one month and one week respectively.

Even though its share price has fallen in the last one month, this stock looks quite good from the point of view of long term investment.

Windlas Biotech Share Price growth chart

The growth chart of Windlas Biotech shows that the company’s share price fell only in 2022, but since then the company has been continuously giving profits. So far in 2024, a growth of 43.68% has been seen in the company’s share.

Windlas Biotech Profit/Loss – Last 4 Years Report

Income Report

Income Report(Cr.)	MAR 24	MAR 23	MAR 22	MAR 21
12 months	12 mths	12 mths	12 mths	12 mths
Revenue From Operations [Gross]	630.96	510.58	463.37	426.71
Revenue From Operations [Net]	630.96	510.58	463.37	426.71
Total Operating Revenues	630.96	513.08	465.93	427.60
Other Income	13.47	9.97	6.71	3.09
Total Revenue	644.42	523.05	472.64	430.70

Expenses

Expenses(Cr.)	Mar 24	Mar 23	Mar 22	Mar 21
12 months	12 mths	12 mths	12 mths	12 mths
Employee Benefit Expenses	87.46	70.32	63.41	58.32
Finance Costs	1.10	0.79	1.42	1.29
Provisions and Contingencies	–	–	–	–
Depreciation And Amortisation Expenses	13.44	12.36	12.15	12.97
Other Expenses	69.22	57.07	46.81	40.18
Total Expenses	567.40	465.99	426.60	387.17

Profit/Loss

Windlas Biotech company has been giving continuous profits for the last 3 years. The total revenue of the company in the financial year 2022 was Rs 472.64 crore on which the company made a profit of Rs 38.09 crore. The total revenue of the company in the financial year 2024 was Rs 644.42 crore and on this revenue the company has earned a profit of Rs 58.19 crore, which is the highest profit in the last 3 years.

Profit/Loss(Cr.)	Mar 24	Mar23	Mar 22	Mar 21
12 months	12 mths	12 mths	12 mths	12 mths
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax	77.02	57.06	46.04	43.53
Profit/Loss Before Tax	77.02	57.06	46.04	11.18

Tax Expenses

Tax Expenses	Mar 24	Mar 23	Mar 22	Mar 21
12 months	12 mths	12 mths	12 mths	12 mths
Current Tax	18.88	14.35	10.13	4.84
Deferred Tax	0.00	0.06	2.66	1.33
Tax For Earlier Years	0.00	0.00	0.00	0.00
Total Tax Expenses	18.88	14.41	7.48	6.17

Profit/Loss After Tax

Profit/Loss After Tax	Mar 24	Mar 23	Mar 22	Mar 21
12 months	12 mths	12 mths	12 mths	12 mths
Profit/Loss After Tax And Before ExtraOrdinary Items	58.14	14.41	38.56	5.01
Profit/Loss From Continuing Operations	58.14	42.64	38.56	5.01
Profit/Loss For The Period	58.14	42.64	38.56	5.01

Other Additional Information

Description	Mar 24	Mar 23	Mar 22	Mar 21
12 months	12 mths	12 mths	12 mths	12 mths
Basic EPS (Rs.)	27.95	19.71	18.81	2.75
Diluted EPS (Rs.)	27.80	19.71	18.81	2.75

Dividend

Dividend	Mar 24	Mar 23	Mar 22	Mar 21
12 months	12 mths	12 mths	12 mths	12 mths
Equity Share Dividend	0.00	7.63	7.63	0.00
Equity Dividend Rate (%)	110.00	80.00	70.00	0.00

Windlas Biotech Balance Sheet – Last 4 Years Report:

Equities and Liabilities

Equities and Liabilities(Cr.)	MAR 24	MAR 24	MAR 24	MAR 24
12 months	12 mths	12 mths	12 mths	12 mths
SHAREHOLDER’S FUNDS
Equity Share Capital	10.40	10.46	10.90	6.41
Total Share Capital	10.40	10.46	10.90	6.41
Reserves and Surplus	439.89	392.20	384.23	192.58
Total Reserves and Surplus	439.89	392.20	384.23	192.58
Total Shareholders Funds	450.29	402.67	395.13	198.99
NON-CURRENT LIABILITIES
Long Term Borrowings	0.00	0.11	0.44	0.83
Deferred Tax Liabilities [Net]	0.00	0.00	0.00	0.68
Other Long Term Liabilities	2.20	3.34	0.24	0.70
Long Term Provisions	2.32	2.02	1.57	1.37
Total Non-Current Liabilities	4.52	5.46	2.25	3.59
CURRENT LIABILITIES
Short Term Borrowings	0.11	0.34	5.68	29.41
Trade Payables	131.11	87.38	62.90	39.93
Other Current Liabilities	39.40	32.72	24.75	23.80
Short Term Provisions	0.73	0.45	0.33	0.28
Total Current Liabilities	171.35	120.88	93.65	93.42
Total Capital And Liabilities	626.16	529.01	491.03	295.99

Assets

Assets(Cr.)	Mar 24	Mar 23	Mar 22	Mar 21
12 months	12 mths	12 mths	12 mths	12 mths
NON-CURRENT ASSETS
Tangible Assets	184.76	108.90	90.73	95.46
Intangible Assets	0.00	0.51	0.45	0.48
Capital Work-In-Progress	0.00	13.80	7.58	0.04
Other Assets	0.00	0.00	0.00	0.00
Fixed Assets	184.76	124.19	99.20	95.98
Non-Current Investments	0.00	0.03	0.03	0.03
Deferred Tax Assets [Net]	0.57	2.03	2.04	0.00
Long Term Loans And Advances	0.00	0.00	0.00	2.98
Other Non-Current Assets	9.59	49.23	8.13	2.85
Total Non-Current Assets	194.92	175.47	109.39	101.84
CURRENT ASSETS
Current Investments	173.44	106.51	64.82	23.14
Inventories	62.19	74.74	58.71	41.46
Trade Receivables	136.28	116.86	110.77	79.41
Cash And Cash Equivalents	30.90	25.45	113.81	30.96
Short Term Loans And Advances	0.00	0.00	0.00	0.00
OtherCurrentAssets	28.44	29.97	33.52	19.19
Total Current Assets	431.24	353.54	381.63	194.16
Total Assets	626.16	529.01	491.03	295.99

Other Additional Information

Other Additional Information	Mar 24	Mar 23	Mar 22	Mar 21
12 months	12 mths	12 mths	12 mths	12 mths
Contingent Liabilities, Commitments
Contingent Liabilities	0.00	14.11	3.25	0.00

Windlas Biotech Quarterly Result

	Mar 24	Dec 23	Sep 23	Jun 23
Sales +	₹175.73Cr.	₹165.37Cr.	₹155.91Cr.	₹147.41Cr.
Expenses +	₹153.17Cr.	₹145.58Cr.	₹137.61Cr.	₹131.07Cr.
EBITDA	₹26.38Cr.	₹23.50Cr.	₹21.93Cr.	₹19.77Cr.
EBIT	₹22.84Cr.	₹20.12Cr.	₹18.60Cr.	₹16.58Cr.
Net Profit	₹16.95Cr.	₹15.10Cr.	₹14.03Cr.	₹12.07Cr.
Profit Before Tax	₹22.56Cr.	₹19.81Cr.	₹18.31Cr.	₹16.35Cr.
Operating Profit Margin	15.40%	14.49%	14.36%	13.65%
Net Profit Margin	9.90%	9.31%	9.19%	8.34%
Earning Per Share	₹8.12	₹7.26	₹6.75	₹5.79
Depreciation	3.54	3.39	3.33	3.19
Dividends Per Share	0.00	7.63	7.63	0.00

Windlas Biotech Share Price Target 2024, 2025, 2026, 2028, 2030, 2040 and 2050

Windlas Biotech Share Price Target 2024

Month	Minimum Target (₹)	Maximum Target (₹)
January	450	480
February	490	510
March	504	511
April	516	535
May	550	600
June	580	605
July	585	600
August	560	590
September	565	580
October	575	588
November	580	600
December	595	610

Windlas Biotech Share Price Target 2025

Month	Minimum Target (₹)	Maximum Target (₹)
January	600	624
February	612	625
March	618	630
April	625	638
May	628	635
June	620	632
July	622	638
August	635	670
September	660	684
October	666	680
November	670	695
December	690	720

Windlas Biotech Share Price Target 2026

Month	Minimum Target (₹)	Maximum Target (₹)
January	700	715
February	710	722
March	705	718
April	715	735
May	720	732
June	716	728
July	725	740
August	735	760
September	755	785
October	760	780
November	762	786
December	780	815

Windlas Biotech Share Price Target 2028

Month	Minimum Target (₹)	Maximum Target (₹)
January	1022	1040
February	1020	1035
March	1030	1065
April	1055	1072
May	1060	1086
June	1062	1092
July	1055	1070
August	1065	1095
September	1090	1128
October	1100	1125
November	1120	1145
December	1140	1170

Windlas Biotech Share Prediction: Expert Opinion

Windlas Biotech Share Price Target 2030

Month	Minimum Target (₹)	Maximum Target (₹)
January	1265	1305
February	1300	1344
March	1308	1328
April	1310	1325
May	1320	1355
June	1350	1368
July	1355	1370
August	1335	1355
September	1352	1377
October	1365	1400
November	1380	1405
December	1400	1440

Windlas Biotech Share Price Target 2040

Month	Minimum Target (₹)	Maximum Target (₹)
January	1933	1955
February	1930	1945
March	1940	1978
April	1965	2005
May	1980	2000
June	1995	2030
July	2000	2015
August	2010	2055
September	2045	2086
October	2080	2110
November	2095	2100
December	2060	2095

Windlas Biotech Share Price Target 2050

Month	Minimum Target (₹)	Maximum Target (₹)
January	2828	2840
February	2835	2880
March	2844	2860
April	2820	2845
May	2825	2860
June	2850	2895
July	2880	2930
August	2920	2960
September	2950	2990
October	2960	2975
November	2940	2962
December	2960	3010

How to Buy Windlas Biotech Share?

There are many brokers available to buy and sell shares of any company in the Indian market. You can buy and sell shares of the company only when you have a demat account. Here a list of many brokers is being given in which you can open your demat account.

• Zerodha
• Groww
• Angel One
• Upstox

Shareholding Pattern

Promoter	62.51%
Other Domestic Institutions	1.65%
Retail and Others	25.55%
Foreign Institutions	1.59%
Mutual funds	8.70%
Total	100.00%

Latest News

• Windlas Biotech promoters have reduced their stake from 62.82% to 62.51% and Mutual Funds have reduced their stake from 10.37% to 8.70%.
• FII/FPI has increased its holding from 1.18% to 1.59% in June 2024.
• The company had net sales of Rs 140.71 crore in March 2023. The company has made total net sales of Rs 171.29 crore this year in March 2024, an increase of 21.73% compared to last year.
• The company’s net profit in the quarter of March 2024 was Rs 16.95 crore, which is 48.05% more than the same quarter last year.
• The company’s EBITDA increased by 40.47% in March 2024 compared to March 2023. The company’s EBITDA in March 2024 stood at Rs 26.38 crore.
• The company has given a return of 162.44% in the last one year.

Strengths

• High TTM EPS Growth: Windlas Biotech’s TTM EPS has registered a significant growth of ₹ 27.96 for the last 12 months, which reflects the efficient management strategy of the company due to which investors are earning good profits on their shares.
• ROE and ROCE improving in last 2 years: For the last 2-3 years, the company has been continuously generating income by using its shareholder’s funds very well and at the same time it has also used its revenue very well, due to which Its ROCE has also increased continuously. ROE and ROCE in FY 23 and 24 are 10.59%, 12.91% and 14.17%, 17.17% respectively.
• Growth in Net Profit: Windlas Biotech has continuously given good profits to investors for the last 4 years. In the financial years 21, 22, 23 and 24, the company has given profits of 5.01Cr, 38.56Cr, 42.64Cr and 58.14Cr, and its profit margin has also increased quarter on quarter. The company’s continued revenue growth reflects its strong potential in the competitive market.
• ‘0’ Debt: Windlas Biotech currently has no debt, which means that if any financial risk comes to it in the future, the company can face it with strength. 0 debt/equity is a good ratio for investors.
• Book Value per share Improving: The book value per share of the company has improved significantly in the last 2 years. Its book value per share in financial years 2023 and 24 was 192.42 and 216.51 respectively. The improvement in book value reflects the increase in its intrinsic value and strong financial position.
• FII / FPI or Institutions increasing their shareholding: Foreign institutional investors (FII), foreign portfolio investors (FPI) and other companies are increasing the shareholding of Windlas Biotech. The growing interest in Windlas Biotech from foreign institutional investors highlights the company’s strong fundamentals and future growth prospects.

Risks

• High P/E And P/B Ratio: The P/E Ratio (TTM) of the company is 25.63 and P/B Ratio is 3.31 which is quite high from the point of view of long term investment.
• Declining Net Cash Flow: The company has seen a loss in net cash, the company is unable to get net cash.

Windlas Biotech Points to Consider Before Investing

1. Windlas Biotech is 9.70% away from its 52 week high zone and 134.29% away from its 52 week low zone.

2. In last 1 month, Nifty 50 has gained 4.89% while Windlas Biotech has recorded a decline of -0.96% which indicates its underperformance.

3. Windlas Biotech’s Market Cap is above the industry level and TTM PE ratio is below the industry level and Net Profit % and Revenue Growth are also below the industry average. It is very important to keep these points in mind from investment point of view.

Competitors of Windlas Biotech

1. Concord Biotech
2. Biocon
3. Sun Pharma Adv
4. Piramal Phytoca
5. DIVISLAB
6. CIPLA
7. ZYDUSLIFE

Similar Stocks

Company Name	Mkt Cap (Rs. Cr.)	Profit (1Year)	52W L	52W H
Biocon Ltd.	40,688	25.41%	217.50	349.45
Concord Biotech Ltd.	14,976	76.38%	741.00	1,725.00
Sun Pharma Advanced Research Company Ltd.	7,216.06	0.29%	178.80	472.80
Marksans Pharma	7049	66.73%	86.20	185.50
Jeena Sikho Lifecare	2647	—	242.78	1,226.80

Profitable Stocks

Company Name	Mkt cap (Rs. Cr.)	Profit (1Year)	52W L	52W H
Ksolves India Ltd	1,343	25.33%	812	1,468
Sat Industries Ltd	1,053	5.54%	73.0	146
Jyoti Resins and Adhesives Ltd	1,719	3.88%	1181	1,780
Neuland Laboratories Ltd	8,211	114.26%	2,727	7,794
Tips Industries Ltd	5924.29	121.74%	210	531

Conclusion

The company has been continuously giving profits and in the last 2 years the company has made a lot of improvement in its ROCE and ROE and the dept on the company is also negligible. After analyzing all these aspects, it can be expected that the company will The share price may increase in future. The company can give very good profits to its investors.

Disclaimer– Please note that all the information given here is for general information purpose only and not for investment purposes. Therefore, before investing in any share, take advice from a certified market expert. If you invest, you will be responsible for your profits and losses.

Also Read:

Then don’t say that I didn’t tell you, buy Waaree Energies shares right now.

Tata Gold Price Target, money printing machine for small investors.

Adani Power price target, share will increase 10 times.

Tata Steel price target, trust of more than 100 years old company.

SW Solar price target, guarantee boom in solar sector.

Tata Power share price target, guaranteed returns.

Yatra Online shares will make you rich, 100% guarantee.

Den Networks Share Price Target 2024, to 2050

Venus Pipes Share Price Target 2023 to 2050